dr. grisham discusses start of phase 2 trial on investigational raf/mek inhibitor in ovarian cancer
Published 3 years ago • 266 plays • Length 6:10Download video MP4
Download video MP3
Similar videos
-
1:59
dr. grisham on mek inhibition in low-grade serous ovarian cancer
-
2:21
phase 2 registration-directed trial of vs-6766 and defactinib
-
1:19
dr. grisham on frontline treatment for low-grade serous ovarian cancer
-
13:10
research update on recurrent low-grade serous ovarian cancer
-
55:39
latest updates in low grade serous ovarian cancer treatment and research
-
43:28
management challenges of low grade serous ovarian/peritoneal cancer - david gershenson
-
0:24
what’s the latest in low-grade serous ovarian cancer?
-
7:15
drug combination shows promise in treatment-resistant advanced ovarian cancer
-
1:50
david gershenson, md, elaborates on the role of mek inhibitor trametinib in lgsc
-
4:53
dr robb hollis: ‘towards new therapies for low grade serous ovarian cancer.’
-
26:02
updates in ovarian cancer: frontline maintenance
-
28:52
gynecologic cancer education: clinical trials update
-
35:35
maximizing the potential of parp inhibitors as first-line maintenance therapy in ovarian cancer
-
30:50
ask the experts: clinical trials in ovarian cancer
-
36:02
ovarian cancer only symposium - understanding clinical trials & the oc roadmap
-
29:51
evaluating clinical pathways for ovarian cancer treatment and maintenance therapy
-
4:06
clinical data from the phase iii prima trial
-
1:13:59
stanford's dr. oliver dorigo on ovarian cancer -- current & novel treatment strategies
-
0:12
high grade serous ovarian cancer simplified